Sven Borchmann Selected Research

Therapeutics

12/2022	JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).
10/2022	Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.
1/2022	Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.
1/2022	Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).
1/2020	Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC.
1/2020	An update on disease biomarkers for Hodgkin lymphoma.
1/2019	The translational science of hodgkin lymphoma.
8/2014	Multi-specific antibodies for cancer immunotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sven Borchmann Research Topics

Disease

16	Neoplasms (Cancer) 02/2024 - 06/2014
15	Hodgkin Disease (Hodgkin's Disease) 01/2023 - 01/2016
3	Residual Neoplasm 02/2024 - 12/2020
3	Lymphoma (Lymphomas) 11/2023 - 12/2020
2	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2018
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2022
1	Neoplasm Metastasis (Metastasis) 01/2020
1	Vitamin D Deficiency 12/2019
1	Obesity 01/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2019
1	Breast Neoplasms (Breast Cancer) 10/2018
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2018
1	Disease Progression 11/2017
1	Carcinoma (Carcinomatosis) 06/2014

Drug/Important Bio-Agent (IBA)

5	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 12/2020
5	Circulating Tumor DNAIBA 11/2023 - 01/2020
5	AntibodiesIBA 10/2022 - 08/2014
5	Cell-Free Nucleic AcidsIBA 06/2022 - 09/2017
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2014
2	Biomarkers (Surrogate Marker)IBA 11/2023 - 01/2020
2	AntigensIBA 10/2022 - 01/2022
2	RNA (Ribonucleic Acid)IBA 10/2022 - 01/2021
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 01/2018
2	Vitamin D FDA LinkGeneric 12/2019 - 11/2017
2	Immune Checkpoint InhibitorsIBA 09/2017 - 01/2016
1	ruxolitinibIBA 12/2022
1	EpitopesIBA 10/2022
1	Toll-Like Receptor 3IBA 10/2022
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2022
1	osimertinibIBA 08/2022
1	B7-H1 AntigenIBA 01/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022
1	Everolimus FDA Link 01/2022
1	InterferonsIBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	Programmed Cell Death 1 ReceptorIBA 12/2020
1	Chimeric Antigen ReceptorsIBA 11/2020
1	Serine (L-Serine)FDA Link 01/2020
1	Cholecalciferol (Vitamin D3)FDA Link 12/2019
1	NivolumabIBA 10/2019
1	infigratinibIBA 10/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2018
1	Brentuximab VedotinIBA 01/2016
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2016
1	Monoclonal AntibodiesIBA 08/2014
1	Carcinoembryonic AntigenIBA 06/2014
1	LigandsIBA 06/2014
1	Recombinant Fusion ProteinsIBA 06/2014

Therapy/Procedure

8	Therapeutics 12/2022 - 08/2014
5	Drug Therapy (Chemotherapy) 01/2022 - 01/2018
2	Immunotherapy 10/2022 - 08/2014
1	Aftercare (After-Treatment) 10/2021
1	Radiotherapy 01/2019